Welcome to our dedicated page for Rapid Micro Biosystems SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rapid Micro Biosystems, Inc. (NASDAQ: RPID) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As an emerging growth company listed on Nasdaq, Rapid Micro Biosystems reports material events, financial results, and financing arrangements through forms such as Form 8-K, as well as its periodic reports on Forms 10-Q and 10-K.
Recent 8-K filings referenced in company communications include results of operations and financial condition for specific quarters and details of a Loan and Security Agreement with Trinity Capital Inc. These filings describe a five-year, $45 million term loan facility, the structure of tranches, interest terms, security interests in company assets, warrant issuance to lenders, and customary covenants and events of default. Other 8-K items incorporate press releases announcing quarterly financial results, including product revenue, service revenue, recurring revenue, and system placement and validation activity.
Through this page, users can review quarterly reports (Form 10-Q), which typically contain more detailed financial statements, segment information, and risk factor updates, and annual reports (Form 10-K), which provide a comprehensive overview of the company’s business, including its Growth Direct system, microbial quality control focus, and role in pharmaceutical manufacturing quality control. Filings related to debt facilities, warrant issuance, and other securities transactions are also accessible.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as revenue composition, recurring revenue trends, capital structure changes, covenant terms, and material events. Users interested in Rapid Micro Biosystems’ regulatory history, financial condition, and obligations under its loan facility can use this page to follow new filings as they are made available through EDGAR.
Rapid Micro Biosystems, Inc. (symbol: RPID) has filed a Form 144 disclosing an insider’s intent to sell shares. Robert G. Spignesi plans to dispose of 11,874 Class A shares on or about 11 July 2025 via NASDAQ, using Fidelity Brokerage Services as broker. At the reference price in the notice, the sale is valued at roughly $39,498.86. The filing cites the shares as recently vested restricted stock received as compensation on 10 July 2025.
The document also lists three prior transactions by the same insider between 8-10 July 2025 totaling 33,688 shares for gross proceeds of $116,981.01. With 39,332,172 shares outstanding, the forthcoming sale represents about 0.03 % of the company’s float, indicating a routine liquidity event rather than a material ownership change.